this is my journL CLUB PRESENTATION CAN YOU CHECK THIS AND PREPARE SOM

this is my journL CLUB PRESENTATION CAN YOU CHECK THIS AND PREPARE SOME QUESTIONS AND ANSWERS THAT COUYLD BE ASKED TO ME BT MTY CONSULTANTS

Reading File

Running Command

cd /tmp/workspace/attachments/2b22984f-22f7-4b4c-9073-c5a617ee1a82 && python3 -c " from pptx import Presentation prs = Presentation('jc august 26.pptx') print('Number of slides:', len(prs.slides)) for i, slide in enumerate(prs.slides, 1): print('---- SLIDE', i, '----') for shape in slide.shapes: if shape.has_text_frame and shape.text_frame.text.strip(): print(shape.text_frame.text) if shape.has_table: tbl = shape.table for row in tbl.rows: print(' | '.join(cell.text for cell in row.cells)) "

Running Command

cd /tmp/workspace/attachments/2b22984f-22f7-4b4c-9073-c5a617ee1a82 && python3 -c " from pptx import Presentation prs = Presentation('jc august 26.pptx') for i, slide in enumerate(prs.slides, 1): if i in [7,8,10,12,22,23,24]: print('---- SLIDE', i, '----') for shape in slide.shapes: print(shape.shape_type, shape.name) if shape.has_text_frame: print(' TEXT:', shape.text_frame.text) if shape.has_table: tbl = shape.table for row in tbl.rows: print(' ROW:', ' | '.join(cell.text for cell in row.cells)) "

Running Command

cd /tmp/workspace/attachments/2b22984f-22f7-4b4c-9073-c5a617ee1a82 && mkdir -p extracted_images && python3 -c " from pptx import Presentation import os prs = Presentation('jc august 26.pptx') for i, slide in enumerate(prs.slides, 1): for shape in slide.shapes: if shape.shape_type == 13: # PICTURE image = shape.image ext = image.ext fname = f'extracted_images/slide{i}_{shape.shape_id}.{ext}' with open(fname, 'wb') as f: f.write(image.blob) print('saved', fname) " ls -la extracted_images/

Running Command

cd /tmp/workspace/attachments/2b22984f-22f7-4b4c-9073-c5a617ee1a82 && python3 -c " from pptx import Presentation prs = Presentation('jc august 26.pptx') for i, slide in enumerate(prs.slides, 1): if i in [8,10,12]: print('SLIDE', i, 'shape count:', len(slide.shapes)) for shape in slide.shapes: print(' ', shape.shape_type, shape.name, getattr(shape,'width',None)) "

Reading File

Running Command

cd /tmp/workspace/attachments/2b22984f-22f7-4b4c-9073-c5a617ee1a82/extracted_images && python3 -c " from PIL import Image for f in ['slide9_4.png','slide23_7.png','slide24_7.png','slide24_9.png']: im = Image.open(f) im.thumbnail((900,900)) im.save(f.replace('.png','_small.jpg'), 'JPEG', quality=70) " ls -la *_small.jpg

Running Command

cd /tmp/workspace/attachments/2b22984f-22f7-4b4c-9073-c5a617ee1a82/extracted_images && python3 -c " from PIL import Image for f in ['slide9_4.png','slide23_7.png','slide24_7.png','slide24_9.png']: im = Image.open(f).convert('RGB') im.thumbnail((900,900)) im.save(f.replace('.png','_small.jpg'), 'JPEG', quality=70) " ls -la *_small.jpg

Reading File

Excellent, this gives full Table 1 data. Now let's check slides 23 and 24 (second study's results tables).

Reading File

Finding Sources

Searching PubMed

"BCG vaccine" AND leprosy

Searching PubMed

"anti-PGL-I" leprosy diagnosis

I reviewed both papers in your journal club deck (BCG vaccination in childhood leprosy - PGIMER; and Slit Skin Smear vs Anti-PGL-I serology - Egypt). Here's a full set of likely consultant questions with model answers, organized by theme. I also pulled one directly relevant recent meta-analysis (PMID 39632641) you should know about in case they push on "is there newer evidence."

Paper 1: BCG Vaccination in Childhood Leprosy (PGIMER, Chandigarh)

Q1. Why is a "BCG scar" used as a proxy for vaccination status, and what is wrong with that? A: Scar presence/absence was used because vaccination cards/records were unavailable retrospectively. It's imperfect - scar formation fails in 1-20% of truly vaccinated people (poor technique, subcutaneous injection, host factors), and scars can occasionally fade over years. So some "unvaccinated" (no-scar) children may actually have received BCG, which would bias results toward the null (dilute the protective effect seen).

Q2. This is a retrospective observational study - what are the inherent limitations, and why wasn't a cohort/case-control design used? A: Retrospective design is subject to recall/selection bias, missing or incomplete records (they explicitly excluded incomplete records, which itself introduces selection bias), no randomization, and cannot establish causality - only association. A prospective cohort comparing BCG card-confirmed vaccinated vs unvaccinated children followed from leprosy contact/exposure would be ideal but is logistically very difficult given leprosy's long incubation period (years).

Q3. How was the diagnosis of leprosy confirmed, and what are the WHO cardinal signs? A: Diagnosis required ≥1 of: (1) definite sensory loss in a hypopigmented/erythematous patch, (2) thickened/enlarged peripheral nerve with sensory loss and/or motor weakness, (3) demonstration of acid-fast bacilli on slit-skin smear. Histopathology was also done at baseline/end of treatment as supportive routine care in most cases.

Q4. What is the Ridley-Jopling classification and how does it differ from the WHO operational classification? A: Ridley-Jopling is an immunopathological spectrum: TT (tuberculoid) - BT - BB (borderline) - BL - LL (lepromatous), reflecting a gradient from strong cell-mediated immunity (TT) to weak CMI/high bacillary load (LL), plus PNL (pure neuritic leprosy). WHO's operational classification (for field/treatment purposes) is simpler: paucibacillary (PB, ≤5 lesions, smear-negative) vs multibacillary (MB, >5 lesions or smear-positive) - used to decide MDT duration/regimen.

Q5. What was the key statistically significant finding, and does it make biological sense? A: Absence of a BCG scar correlated significantly with predisposition to multibacillary disease - 10/11 unvaccinated children were at the lepromatous pole (5 BL, 5 LL). Biologically this fits: BCG's immunomodulatory/Th1-priming effect is thought to shift the immune response toward the tuberculoid (paucibacillary) pole and away from the anergic lepromatous pole, similar to its heterologous, non-specific innate-training effects seen with other mycobacterial antigens.

Q6. What was the actual p-value/statistical test used for that finding, and was multivariate adjustment for confounders (age, nutrition, contact exposure) done? A: The slide doesn't explicitly show the p-value or the test (likely chi-square/Fisher's exact given small cell counts) - you should verify this directly from the paper's results/table before presenting, since with an unvaccinated group of only 11, cell counts are very small and a consultant may ask you to justify use of Fisher's exact test versus chi-square, and whether confounders (nutritional status, degree of household contact/bacillary exposure, HLA/genetic susceptibility) were adjusted for. Based on the slide content alone, no multivariate adjustment was mentioned - this is worth flagging as a limitation if true.

Q7. Why do BT-spectrum patients show more persistent skin lesions (7/11, 63.6%) even though tuberculoid disease is considered "milder"? A: BT is immunologically unstable - it lies close to the midpoint of the spectrum and is prone to "downgrading" or delayed clinical/histological resolution even after adequate MDT, because residual granulomatous inflammation and nerve involvement can persist longer than the bacillary clearance. This is different from LL, where lesions may look diffuse but are more histologically stable to therapy despite higher bacillary index.

Q8. Why did the proportion of childhood leprosy (4.62%) not show a clear decreasing trend compared to the 2001-2011 study (4.8%)? A: This suggests transmission is ongoing and elimination programs (post-2005 "elimination" declaration in India) have plateaued rather than continuing to decline - possibly due to under-detection, reduced active case-finding after leprosy was "eliminated" as a public health problem (prevalence <1/10,000), and reduced surveillance funding, not necessarily true reduction in transmission.

Q9. Sample size was only 50 - was a power calculation done? Can you draw firm conclusions on reactions/disability from such small numbers? A: No power calculation is mentioned; this is explicitly listed as a limitation. With only 6 reaction cases and 11 disability cases total, subgroup comparisons (e.g., reactions in vaccinated vs unvaccinated) have very wide confidence intervals and limited statistical power - findings should be considered hypothesis-generating, not confirmatory.

Q10. Is there any more recent, larger-scale evidence on BCG's protective efficacy against leprosy specifically (not just TB)? A: Yes - a 2024 systematic review and meta-analysis of RCTs, "Efficacy of leprosy vaccines across the globe" (Dasgupta et al., Indian Journal of Medical Research, PMID 39632641), specifically pooled trial data on BCG and other candidate vaccines (e.g., MIP) against leprosy. Worth mentioning if a consultant asks about the strength of evidence beyond this single retrospective study - it would let you show you've looked beyond the assigned paper.

Q11. What does "MIP" refer to, mentioned in your conclusion? A: Mycobacterium indicus pranii - an alternative immunoprophylactic/immunotherapeutic mycobacterial vaccine studied in India as an adjunct to BCG or MDT for leprosy, particularly of interest for household contacts.

Paper 2: SSS vs Anti-PGL-I Serology

Q12. Why is slit-skin smear (SSS) considered a poor standalone test, and why is it still the WHO-recognized cardinal sign despite low sensitivity? A: SSS sensitivity is low (especially in paucibacillary/early disease with low bacillary load) and is highly technique- and reader-dependent. It remains the WHO cardinal sign because it is specific, cheap, requires no advanced infrastructure, and directly demonstrates the organism - important for field-level programs in resource-limited, high-burden settings even though it misses early/PB cases.

Q13. Why did all paucibacillary (TT and BT) cases test negative on SSS in this study - doesn't that undermine SSS's utility entirely? A: PB/tuberculoid-spectrum disease has a low bacillary load by definition (strong cell-mediated immunity controls the organism), so acid-fast bacilli are often below the detection threshold of smear microscopy. This is an expected and previously reported finding, not a flaw in technique - it's precisely why serology (or PCR) is proposed as an adjunct for these smear-negative-but-clinically-suspicious cases.

Q14. Explain what Anti-PGL-I (phenolic glycolipid-I) is and why IgM against it is used diagnostically. A: PGL-I is a species-specific glycolipid in the M. leprae cell wall. High bacillary loads (MB/LL disease) generate a strong IgM antibody response to PGL-I, so titers correlate with bacillary burden - hence higher sensitivity in MB and lower in PB (fewer bacilli, weaker antibody response). It is a marker of exposure/bacillary load, not necessarily of active clinical disease, so it can also be positive in some healthy household contacts.

Q15. How do you interpret the ROC curve findings, and what does AUC tell you here? A: The ROC curve plots sensitivity vs (1-specificity) across cutoffs for each test. In their PB-diagnosis ROC comparison, the anti-PGL-I curve is above and to the left of the SSS curve, meaning better discrimination (higher AUC) - anti-PGL-I identifies more true PB cases at a given false-positive rate. If asked for you exact AUC figures, note the slide/table with AUC/95% CI wasn't included in your extracted excerpt - check the paper's ROC statistics table before presenting exact values.

Q16. Why were patients with lepra reactions and those already treated >3 months excluded? A: Reactions (Type 1/Type 2 ENL) alter the local immune/inflammatory picture and can transiently affect antibody titers and clinical/histological findings, confounding diagnostic accuracy assessment. Prior treatment reduces bacillary load and antibody titers, which would artificially lower SSS/serology positivity and bias sensitivity estimates downward - excluding them isolates "de novo diagnostic performance."

Q17. This is a cross-sectional study - what does that mean for causal or prognostic claims, and could there be spectrum bias? A: Cross-sectional design only tells you diagnostic performance at one time point in patients already clinically suspected of leprosy (not a general population screen), so sensitivity/specificity figures may not generalize to asymptomatic contacts or population screening. Spectrum bias is a real concern here - if their sample was weighted toward advanced/MB cases, sensitivity of both tests would appear inflated relative to a true early-detection population.

Q18. Why did the study restrict serology to IgM anti-PGL-I only, and would testing IgG or combined isotypes change the results? A: IgM is the dominant/classic isotype used because it best reflects bacillary load in most studies, and assay kits are typically IgM-based. IgG or IgA anti-PGL-I, or combined isotype panels, have been explored in other studies (e.g., to differentiate leprosy patients from exposed but healthy contacts) and might improve sensitivity/specificity further - the authors themselves list "restriction to IgM only" as a limitation.

Q19. Practically, how would you use both tests together in a peripheral health center? A: Use SSS as the first-line, specific confirmatory test (per WHO), and reserve anti-PGL-I serology as an adjunct for smear-negative but clinically-suspicious (especially PB) cases to avoid missing early disease, and potentially for screening household contacts. A sequential/parallel testing strategy improves overall sensitivity without sacrificing the specificity SSS provides.

Cross-cutting / General Questions (likely from both papers)

Q20. What's the difference between a systematic review/meta-analysis and single observational studies like these - how much weight should we give this evidence? A: Both papers are single-center, non-randomized studies (retrospective cohort and cross-sectional respectively) - lower on the evidence hierarchy than RCTs or meta-analyses. They generate hypotheses and are useful for local epidemiology and test-performance estimates, but confirmatory conclusions (e.g., "BCG protects against MB leprosy") need larger, ideally prospective, multi-center data.

Q21. Type 1 vs Type 2 (ENL) lepra reactions - what's the difference? A: Type 1 (reversal) reactions occur in borderline (BT/BB/BL) disease due to abrupt increase in cell-mediated immunity against M. leprae antigens, causing existing lesions to become inflamed/edematous, with possible new nerve damage - not vasculitic. Type 2 (Erythema Nodosum Leprosum, ENL) occurs in BL/LL (MB) disease, is immune-complex mediated (Type III hypersensitivity), and presents with crops of tender erythematous nodules, fever, and systemic features.

Q22. What is the WHO disability grading system referenced (Grade 1/Grade 2)? A: Grade 0 = no disability. Grade 1 = loss of protective sensation in hands/feet or eyes without visible deformity. Grade 2 = visible deformity or damage present (e.g., clawing, ulcers, lagophthalmos, corneal opacity) - used as a program indicator of late diagnosis/treatment delay.

Q23. Both studies had "no funding/no conflicts of interest" - why does that matter to a journal club audience? A: It reduces (though doesn't eliminate) concern about sponsor-driven bias in design or reporting, which is particularly relevant for diagnostic-test-comparison and vaccine-related studies where commercial serology-kit manufacturers or vaccine producers could otherwise have a stake in favorable results.

Q24. If you were to design a follow-up study addressing these limitations, what would you do differently? A: Multi-center, adequately powered prospective design; documented BCG vaccination card/registry data rather than scar as proxy; standardized reaction and disability grading with blinded assessors; multivariate regression adjusting for age, contact intensity, nutritional status, and genetic susceptibility (e.g., HLA typing); and for the diagnostic-accuracy paper, inclusion of PCR/qPCR for M. leprae DNA as an additional reference/comparator, plus paired sampling (SSS + serology + biopsy) in every patient.

A quick honesty note: a few numeric details your consultants may drill into (exact p-values, ROC AUC with 95% CI, and the SSS/APGL-I sensitivity-specificity percentages) weren't fully legible/complete in the results table images embedded in your slides. I'd recommend pulling up Table 2/3 and the ROC statistics table from the original papers before your presentation so you can quote the exact numbers if pressed - I've flagged those specific spots above (Q6, Q9, Q15) as the ones most likely to get a "what was the actual number/p-value" follow-up.

This is a shared conversation. Sign in to Orris to start your own chat.